Pharmacoeconomics and Management in Pharmacy IXstsimonpharmacy.com/docs/Pharmacoeconomics and...

2011 [UNIT PH 3340] 1

Pharmacoeconomics and

Management in Pharmacy IX

[John Vella B.Pharm.(Hons.) M.Sc.(Pharmacoeconomics)]

2011 [UNIT PH 3340] 2

Pharmacoeconomics:

a round-up of the basic

principles

[John Vella B.Pharm.(Hons.) M.Sc.(Pharmacoeconomics)]

J. Vella [PH 3340]

Pharmacoeconomics

• The combination of healthcare and

economics is never an easy marriage

• Medical care and cold, hard figures do not

mix easily

• Healthcare issues are necessarily based on

emotional grounds, whereas the distributive

functions of expenditure evaluations are not

3

J. Vella [PH 3340]

Basic PE Definitions

• Pharmacoeconomics:

– The description and analysis of the costs and consequences

of pharmaceutical products and services and their impact on

individuals, health care systems and society. (Bootman JL,

1995)

• Pharmaceutical care:

– The responsible provision of drug therapy for the purposes of

achieving definite outcomes. (Hepler and Strand, 1990)

• Outcomes research:

– Broadly defined as studies that attempt to identify, measure

and evaluate the end result of health care services in

general. (Bootman JL, 1995)

J. Vella [PH 3340]

The ECHO model

• This was defined by Kozma in 1995 as a

refinement of the Hepler and Strand

definition of pharmaceutical care, with

respect to the field of PE evaluations

• It states that outcomes research (PE

studies) consist of the amalgamation of the

clinical, humanistic and economic facets of

the issue

5

J. Vella [PH 3340]

CLINICAL

(C)

ECONOMIC

(E)

HUMANISTIC

(H)

OUTCOMES RESEARCH

(O)

The ECHO Model

2011 [UNIT PH 3340] 7

The role of PE

[John Vella B.Pharm.(Hons.) M.Sc.(Pharmacoeconomics)]

J. Vella [PH 3340]

Why study Pharmacoeconomics?

Health Expenditures as a % of GDP by Country

0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

18.0

1970

1975

1980

1985

1990

1995

2000

2005

Year

% G

DP

Canada

France

Germany

Japan

United Kingdom

United States

J. Vella [PH 3340]

Why indeed?

• Healthcare costs are rising all around

• Focus is on spending less and getting more

• This has led to a rise in the importance of PE

in the field of pharmaceutical healthcare

• The financial crisis in the last years has

accentuated the need for proper budgeting

and data analysis

9

J. Vella [PH 3340]

But when it comes to outcomes…

Life Expectancy at Birth by Country

60

63

66

69

72

75

78

81

84

1961

1966

1971

1976

1981

1986

1991

1996

2001

2004

YEAR

Years

of

Lif

e

Canada

France

Germany

Japan

UK

US

J. Vella [PH 3340]

PE in society

• Can have macro- or micro-economic uses

• Macro-economic factors refer to decisions

that effect a country or region as a whole,

such as total healthcare expenditures and

employment figures

• Micro-economic factors refer to individual

decisions with respect to specific issues,

such as the introduction of a particular

medicine 11

J. Vella [PH 3340]

Specific Decisions for PE Applications

Clinical Decisions

Formulary Management

Drug Use Guidelines

Disease Management

Resource Allocation

MICRO

MACRO

Justification of Pharmacy Services

J. Vella [PH 3340]

Local examples

• An example of a macro-economic factor to

study are local healthcare expenditures over

the last decade.

• These have doubled from 34 Million Euro to

76 Million Euro

• A micro-economic discussion involved the

controversy regarding Herceptin and the

local public healthcare system

13

J. Vella [PH 3340]

The development of PE

• In the last 20 years PE has gone from being

a new discipline to one that is at the forefront

of most medical and healthcare issues

• The cost of healthcare has come to the fore,

especially in recent years as the financial

crisis has impacted all areas

• PE has become the Solomonic distributor of

healthcare justice

14

2011 [UNIT PH 3340] 15

Types of PE evaluations

[John Vella B.Pharm.(Hons.) M.Sc.(Pharmacoeconomics)]

J. Vella [PH 3340]

Stages in economic evaluation

Deciding upon study question

• Viewpoint taken.

• Alternatives appraised.

Assessment of costs and benefits

• Identification of relevant C&B.

• Measurement of C&B.

• Valuation of C (&B).

Adjustment for timing.

Making a decision.

Adjustment for uncertainty.

J. Vella [PH 3340]

Types of PE studies

Type of Study Description

Cost Minimisation Analysis – CMA Compares costs in monetary terms of

treatments with identical outcomes

Cost Effectiveness Analysis – CEA Compares costs in monetary terms with

outcomes in natural units

Cost Utility Analysis – CUA Compares costs in monetary terms &

outcomes in terms of years of life

Cost Benefit Analysis - CBA Compares costs and outcomes in

monetary terms

17

2011 [UNIT PH 3340] 18

Benchmarking PE studies

[John Vella B.Pharm.(Hons.) M.Sc.(Pharmacoeconomics)]

J. Vella [PH 3340]

What must we believe?

• All studies must be scrutinised carefully

19

Aim Clear and direct

Methodology Logical and repeatable

Type of PE study Applicable to the situation

Perspective Personal, societal,

prescriber

Results Statistics should significant

Conflicts Grants or employment

Publishing authority Credible and reknown

J. Vella [PH 3340]

“Applied Pharmacoeconomics”

• Defined as :

– “Putting pharmacoeconomic principles, methods

and theories into practice, to quantify the “value”

of pharmacy products and pharmaceutical care

services utilized in “real-world” environments”

Sanchez LA, 1997

J. Vella [PH 3340]

Applied PE

• Is the sum of all the examples we discussed

in the previous lectures

• The practical use of the knowledge and skills

accumulated by the study of pharmaceutical

and economic data

• As a discipline in its infancy, it is not well

understood, both internally and externally

21

J. Vella [PH 3340]

Bibliography and Acknowledgements

• Deshpande PR, PharmD, Dept. of Pharmacy Practice, Manipal University, Manipal, India. Pharmacoeconomics,

Microsoft Powerpoint Presentation

• Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health

Care Programmes. 3rd ed Oxford: Oxford University Press; 2007

• Heaton A BS (Pharm), Pharm. D., RPh.Director of Pharmacy BlueCrossBlueShield of Minnesota, Performance

Enhancing Pharmaceuticals, Microsoft Powerpoint Presentation

• International Society for Pharmacoeconmics and Outcomes Research (ISPOR), Introduction to

Pharmacoeconomics, ISPOR Distance Learning Program

• Rascati, K. Essentials of Pharmacoeconomics; Philadelphia:LippincottWilliams & Wilkins; 2008

• Ridker et al, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

NEJM, 359 (21), 2008

• Sale, L. Critical Appraisal of Research Reports, Department of Reproductive Health and Research, WHO,

Geneva, 2006

• Satyanarayana K, St.Peter’s Institute of Pharmaceutical Sciences, Pharmacoeconomics, Microsoft Powerpoint

Presentation

• Shull S PharmD, MBA. Basics of Pharmacoeconomics and Outcomes Research:Application to Patient Care,

Microsoft Powerpoint Presentation

• Quick J, Director, Essential Drugs and Medicines Policy – EDM, Health Technology and Pharmaceuticals

Cluster – HTP, World Health Organization, June, 2002Presentation

22

J. Vella [PH 3340]

Bibliography and Acknowledgements

• Smith R, Wright D. Health Economics for Prescribers, Microsoft Powerpoint Presentation

• Vella J. Medicine prices in Malta and their relation to economic indicators. Dissertation, University of Malta

2010

• Vella J. Essays in Pharmacoeconomics: The QALY as a tool in evaluating treatment outcomes. Unpublished

work, 2010

• www.nso.gov.mt, National Statistics Office website

23